Evidence map›Paper›PMID 29067332›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2017

UB-311, a novel UBITh

Chang Yi Wang, Pei-Ning Wang, Ming-Jang Chiu, Connie L Finstad, Feng Lin, Shugene Lynn, Yuan-Hung Tai, Xin De Fang, Kesheng Zhao, Chung-Ho Hung and 6 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04075318 (A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine), which is not on this map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04075318 phase1completednot on this mapstarted 2019, after this paper: background citation

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease

TypeinterventionalSponsorUnited Neuroscience Ltd.Ran2019 to 2023Enrolled70ConditionsParkinson's Disease, ParkinsonismArmsUB-312, Placebo
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 139 citations in OpenAlex.

  1. A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.Movement disorders : official journal of the Movement Disorder Society · 2022
    Trial
  2. Review
  3. Article
  4. Article
  5. Advances in the treatment of Alzheimer's disease.Frontiers in pharmacology · 2026
    Review
  6. Review
  7. Vaccines for Alzheimer's disease: a brief scoping review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Microglial activation states and their implications for Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2025
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Chang Yi WangUnited Biomedical, Inc. (UBI), Hauppauge, NY, USA.
Pei-Ning WangDepartment of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan.
Ming-Jang ChiuDepartment of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
Connie L FinstadUnited Biomedical, Inc. (UBI), Hauppauge, NY, USA.
Feng LinUnited Biomedical, Inc. (UBI), Hauppauge, NY, USA.
Shugene LynnUnited Biomedical Inc., Asia (UBI-Asia), Hsinchu, Taiwan.
Yuan-Hung TaiUnited Biomedical Inc., Asia (UBI-Asia), Hsinchu, Taiwan.
Xin De FangUnited Biomedical, Inc. (UBI), Hauppauge, NY, USA.
Kesheng ZhaoUnited Biomedical, Inc. (UBI), Hauppauge, NY, USA.
Chung-Ho HungUnited Biomedical, Inc. (UBI), Hauppauge, NY, USA.
Yiting TsengUnited Neuroscience, Inc. (UNS), Hsinchu, Taiwan.
Wen-Jiun PengUnited Biomedical Inc., Asia (UBI-Asia), Hsinchu, Taiwan.
Jason WangUnited Biomedical Inc., Asia (UBI-Asia), Hsinchu, Taiwan.
Chih-Chieh YuUnited Neuroscience, Inc. (UNS), Hsinchu, Taiwan.
Be-Sheng KuoUnited Biomedical, Inc. (UBI), Hauppauge, NY, USA.
Paul A FrohnaUnited Neuroscience, Inc. (UNS), Hsinchu, Taiwan.
United Biomedical (United States) · USAsia University · TWGlobal Unichip (Taiwan) · TWNational Taiwan University Hospital · TWTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA novel amyloid β (Aβ) synthetic peptide vaccine (UB-311) has been evaluated in a first-in-human trial with patients of mild-to-moderate Alzheimer's disease. We describe translational research covering vaccine design, preclinical characterization, and phase-I clinical trial with supportive outcome that advances UB-311 into an ongoing phase-II trial.

methodsUB-311 is constructed with two synthetic Aβ

resultsUB-311 covers a diverse genetic background and facilitates strong immune response with high responder rate. UB-311 reduced the levels of Aβ DISCUSSION: The UBITh

Indexed as

Alzheimer's diseaseAmyloid β vaccineFIH clinical trialUB-311UBITh® platform

Identifiers

PMID29067332
PMCPMC5651432
OpenAlexW2605942834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.